Biophytis S.A. - ADR (BPTSY)

Overview

Biophytis S.A. is a pioneering clinical-stage biotechnology firm focused on crafting therapeutics designed to decelerate degenerative processes and enhance functional outcomes for individuals afflicted with age-related ailments. The company prides itself on developing treatments that target and trigger critical biological resilience pathways. These pathways offer protection against and counter the adverse effects inflicted by multiple biological and environmental stresses. These stresses include inflammatory, oxidative, metabolic, and viral stresses, all of which contribute to the onset of age-related diseases. Founded in 2006, Biophytis has positioned its headquarters in Paris, France, reflecting its commitment to advancing health technology and addressing the global challenge of aging populations.

Products and Services

• BIO101

Biophytis's flagship drug candidate, BIO101, is an oral small molecule under development aimed at treating a spectrum of neuromuscular diseases, among which are sarcopenia and Duchenne muscular dystrophy (DMD), alongside obesity. Furthermore, BIO101 is being explored as a potential remedy for severe respiratory failure in patients afflicted by COVID-19. This demonstrates the company’s adaptive approach in responding to global health emergencies by repositioning its drug candidates to meet urgent medical needs.

• BIO201

In addition to BIO101, Biophytis is developing BIO201, another oral small molecule. This promising candidate is geared towards the treatment of various retinopathies, notably including dry age-related macular degeneration (AMD) and Stargardt disease. Drawn from the same innovative approach to leveraging biological resilience pathways, BIO201 represents a crucial step in Biophytis' effort to confront and manage age-related visual impairments, thereby enriching the quality of life for the elderly.

Further augmenting its research and development efforts, Biophytis S.A. has entered into a collaboration agreement with AFM-Telethon. This partnership primarily supports the development of BIO101 in the fight against DMD, underlining the company's dedication to contributing valuable solutions to rare and debilitating conditions. Through such initiatives, Biophytis S.A. affirms its strategic position in the biotechnology landscape, reinforcing its mission to usher in novel therapeutics for age-related diseases.